WASHINGTON, Aug. 9 (UPI) -- The U.S. Food and Drug Administration said Wednesday it has set up a task force to study how to regulate nanotechnology products.
The internal task force will focus on possible adverse health effects from FDA-regulated products that employ nanotechnology materials and recommend ways to address any knowledge or policy gaps in this area.
"As this exciting new area of science develops, FDA must be positioned to address both health promotion and protection challenges that it may present," said Andrew von Eschenbach, the FDA's acting commissioner. "Through this task force, we are leveraging our expertise and resources to guide the science and technology in the development of nanotechnology-based applications."
The task force will hold a public meeting Oct. 10 to discuss new and emerging scientific issues pertaining to biological interactions of nanotech products that could lead to beneficial or adverse health effects.